| dc.description.abstract | Diflunisal is a nonsteroidal anti-inflammatory drug that is known effective in treating fever, pain, and inflammation in human and was approved by the FDA in
3
April 1982. The in silico screening was performed and Diflunisal came up as a potential alternative that can be used to treat breast cancer, especially triple-negative breast cancer. It is believed to tackle PIM1 Kinase, an enzyme that shows over expression on triple-negative breast cancer (TNBC) tumors. , which helps promote the cell growth. However, the clinical effect on TNBS is unknown whereas the molecule will be interfered by other molecules when it enters human body. In this study, we investigated the cytotoxicity of Diflunisal on two different breast cancer cell lines MDA-MB-231 and MCF-7 by MTS assay. Thereafter, wound healing assay was carried out to examine the effect of Diflunisal on cell migration of both cell lines. The results have showed that Diflunisal showed significant impact on both viability and migration rate of MDA-MB-231 and MCF-7 cell line (P < 0.05), compared to the untreated cells. Nevertheless, influence of Diflunisal on viability and migration rate is not significantly different between two cell lines (P > 0.05).
This finding provides information on the usage of bioinformatic tools on screening for potential drugs. In addition, further experiments should be conducted so that mechanism of Diflunisal exerting effect on breast cancer cell lines can be confirmed.
Keywords: Triple-negative breast cancer, TNBC, Diflunisal, MDA-MB-231, MCF-7. | en_US |
